A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Weight Loss

← catalyst calendar

NCT07663630 · readout in 531 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · Quadruple · Supportive care

Enrollment

80estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-22

estimated

When the study began enrolling

Primary completion

2028-02-02

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-03-29

estimated

The whole study's end, after follow-up

First posted

2026-06-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non-small Cell Lung Cancer (NSCLC)
Cachexia

Interventions

Drug: ponsegromab
Drug: placebo

Primary outcome

what the primary-completion date above is the date OF

Percent change from baseline in Lumbar Skeletal Muscle Index

measured Baseline, Week 12

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed